eif-4e

4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.

4E2RCat is an inhibitor of eIF4E-eIF4G interaction (IC50 = 13.5 μM) and effectively blocks coronavirus replication, as evidenced by reduced viral protein expression and decreased production of infectious virus.

4EGI-1, a competitive eIF4E/eIF4 g interaction inhibitor, binds to eIF4E(KD=25 μM).

eIF4E-IN-3 is a highly effective inhibitor of eukaryotic initiation factor 4e (eIF4e), exhibiting noteworthy potential for investigating eIF4e dependent diseases, particularly cancer research (WO2021003157A1, compound 485).

eIF4E-IN-1 (WO2021003194A1, compound Y), is a highly effective inhibitor of eIF4E, a key protein involved in immunosuppression. By targeting immune checkpoint proteins such as PD-1, PD-L1, LAG3, TIM3, and IDO, eIF4E-IN-1 functions to disrupt immune suppression and promote immune release in specific diseases such as cancer and infectious diseases.

eIF4E-IN-2 is a highly effective inhibitor of eukaryotic initiation factor 4e (eIF4e). This compound exhibits significant potential in the investigation of eIF4e dependent diseases, particularly in the context of cancer research.